Financial Performance - The company achieved operating revenue of 142.27 million yuan, a decrease of 0.29% compared to the same period last year[4] - Net profit attributable to shareholders increased by 1.00% to 26.67 million yuan[4] - Net profit attributable to shareholders after deducting non-recurring gains and losses decreased by 14.14% to 22.25 million yuan[4] - Basic earnings per share decreased by 4.00% to 0.72 yuan[4] Assets and Equity - Total assets at the end of the reporting period were 267.18 million yuan, an increase of 37.20% from the beginning of the period[4] - Shareholders' equity attributable to the company increased by 54.55% to 193.02 million yuan[4] - The total share capital increased by 23.81% to 43.33 million yuan[4] - The net asset value per share attributable to shareholders increased by 24.65% to 4.45 yuan[4] Expenses and Operations - The increase in sales and management expenses was attributed to the expansion of the marketing network and the company's listing on the Beijing Stock Exchange[6] Reporting and Auditing - The financial data presented are preliminary and unaudited, with final figures to be disclosed in the annual report[7]
博迅生物(836504) - 2023 Q4 - 年度业绩